1 pm



CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450,

HUESCHEN AND SAGE

Michel Custon 2008

SERVIER 403 DIV

Applicant

Gilbert LAVIELLE, Olivier MULLER, Mark MILLAN, and

Alain GOBERT

Serial No. :

10/813,347

Filed

March 30, 2004

Title

Indoline Compounds

Art Unit

1625

Examiner:

Evelyn M. HUANG, Esq.

Honorable Commissioner for Patents PO Box 1450 Alexandria, VA 22313

SUPPLEMENTAL RESPONSE UNDER 37 CFR § 1.111

Sir:

Responsive to the Office action, dated October 15, 2004, and to supplement the Response and Amendment of March 14, 2005, please find enclosed herewith a copy of Form PTO-1449 (which was submitted with the previous Response) and the remaining references which accompany this form.

It should be apparent that the undersigned attorney has made an earnest effort to place this application into condition for immediate allowance. If he can be of assistance to the Examiner in the elimination of any possibly-outstanding insignificant impediment to an immediate allowance, the Examiner is respectfully invited to call him at his below-listed number for such purpose.

Allowance is solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

G. PATRICK SAGE

Dated: March 21, 2005 Customer No.: 25,666 500 Columbia Plaza 350 East Michigan Ave. Kalamazoo, MI 49007-3856 (269) 382-0030

Enclosure:

Copy of PTO-Form 1449 and Accompanying References (references

8, 21, and 22) and Postal Card Receipt

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

APPLICANT	R ART CITED BY	SERVIER 403 [DIV	10/813,347						
SHEET 1 OF 3		APPLICANT G. LAVIELLE, C	APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT							
	MAR 2 4 2005	FILING DATE March 30, 2004	1	GROUP 1625						
	TRADEMAR	U.S. PATEN	IT DOCUMENTS	;						
Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	S SUB- CLASS	FILING D APPROF				
		FOREIGN PAT	ENT DOCUMEN	ITS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLAT				
						YES	NO			
		OTHER	PRIOR ART							
		al., Psychopharmaco	ology, 1990 , 101,							
		ropean Journal of Ph								
	O'NEILL, et al., Pharmacology, Biochemistry, and Behavior, 1999, 63, 237-243.									
	REAVILL, et al., British Journal of Psychopharmacology, 1999, 126, 572-574.									
		, et al., Journal of Pha		·	apeutics, 2	<u>2000,</u> 295,	226-232.			
		ig Development Rese								
	PAIVA, et al., Psychopharmacology, 1988, 96, 395-399.									
	DUGOVIC, Journal Sleep Research, 1992, 1, 1163-1168.									
	LANDOLT, et al., Neuropsychopharmacology, 1999, 21, 455-466.									
	SHARPLEY, et al., Biological Psychiatry, 2000, 47, 468-470.									
	WATSON, et al., F	Pharmacology, Bioch	emistry, and Ber	navior, 1991 , 39, 6	05-612.					
EXAMINER	DATE CONSIDER	(ED								

. . .

PTO-1449	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347
LIST OF PRIOR ART CITED BY APPLICANT		
SHEET 2 OF 3		
(है)	APPLICANT G. LAVIELLE, O. MULLER, M. M	ILLAN, and A. GOBERT
MAR 2 4 2005 -	FILING DATE	GROUP
TRADEMARK CH.	March 30, 2004	1625

OTHER PRIOR ART

OTHER PRIOR ART
FOREMAN, et al., <i>Life Sciences</i> , 1989 , <i>45</i> , 1263-1270.
KLINT, et al., Psychopharmacology, 1995, 119, 291-294.
HIRSCHFELD, Journal of Clinical Psychiatry, 60 Suppl. 17:32-35, 1999.
POPOVA, et al., Neuroendocrinology, 2002, 76, 28-34.
Amesergide, LY-237733; Pharmaproject, Phase II Clinical Trial, 2005
KOSKINEN, et al., Pharmacology, Biochemistry and Behavior, 2000, 66, 729-738.
WHITE, et al., Pharmacology, Biochemistry and Behaviour, 1991, 39, 729-736.
MILLAN, et al., Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 581-591.
MUNDO, et al., International Clinical Psychopharmacology, 2000, 15, 69-76.
MILLAN, et al., <i>Prog. Neurobiol.</i> , 1999 , <i>57</i> , 1-164.
MILLAN, et al., <i>Prog. Neurobiol.</i> , 2002 , <i>66</i> , 355-474.
KALKMAN, et al., Int. J. Clin. Pharmacol. Res., 1997, 17, 75-77.
KALKMAN, et al., Naunyn Schmiedebergs. Arch. Pharmacol., 1994, 350, 225-229.
KALKMAN, et al., <i>Life Sci.</i> , 1994 , <i>54</i> , 641-644.
Ro-60-0759, Pharmaproject, Preclinical Trial, 2005
SB-243213, Pharmaproject, Phase I Clinical Trial, 2005
DATE CONSIDERED
•

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347
LIST OF PRIOR ART CITED BY APPLICANT		
SHEET 3 OF 3		
	APPLICANT G. LAVIELLE, O. MULLER, M. M	ILLAN, and A. GOBERT
MAR 2 4 2005	FILING DATE March 30, 2004	GROUP 1625

OTHER PRIOR ART

<u></u>
. 10
gh citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.